Baseline characteristics	Interventional CVP cohort (N=3)	Surgical CVP cohort (N=8)
Age in years (mean±SD)	79.7 (3.5)	67.6 (17.4)
Female (%)	3 (100)	5 (62.5)
Arterial hypertension (%)	3 (100)	7 (87.5)
Diabetes mellitus (%)	-	5 (62.5)
Hyperlipoproteinemia (%)	3 (100)	4 (50.0)
Atrial fibrillation (%)	1 (33.3)	2 (25.0)
Stroke characteristics		
Prestroke mRS score (median; Q1, Q3)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
NIHSS at onset (median; Q1, Q3)	19 (13, 22)	23 (14, 32)
ASPECTS (median; Q1, Q3)	5.0 (5.0, 6.0)	8.0 (7.0, 9.0)
Intravenous tPA (%)	-	1 (12.5)
Location of occlusion		
Tandem occlusion (%)	-	1 (12.5)
ICA (%)	-	1 (12.5)
M1 proximal (%)	1 (33.3)	2 (25.0)
M1 distal (%)	1 (33.3)	-
M2 (%)	1 (33.3)	-
Posterior circulation (%)	-	4 (50.0)
Outcome		
mRS score at 90 days (median; Q1, Q3)	4.0 (3.5, 5)	5.5 (4, 6)
Mortality at 90 days (%)	1 (33.3)	4 (50.0)
Good outcome (%)	0 (0.0)	2 (25.0)

Table S1: Baseline characteristics and outcome of patients with stroke after cardiovascular procedures divided into an interventional cohort (without use of cardiopulmonary bypass) and a surgical cohort (with use of cardiopulmonary bypass). Categorical variables are shown as absolute numbers and percentages. Continuous

variables are described by mean ± standard deviation (SD) or median and the 1st and 3rd Quartile (Q1, Q3).

ASPECTS Alberta stroke programme early CT *score*; *ICA* intracranial carotid artery; *mRS* modified Rankin scale; *M1* first segment of middle cerebral artery; *M2* second segment of middle cerebral artery; *NIHSS* National Institutes of Health Stroke Scale; *tPA* tissue plasminogen activator.